منابع مشابه
Pregabalin Use Disorder.
Pregabalin is a gamma-aminobutyric acid (GABA) analog used for the treatment of partial epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. As a GABA analog, there has been some concern about its abuse liability. The number of case reports on the abuse potential of pregabalin has increased (1,2,3,4). To our knowledge, this is the third case report of pregabalin use disor...
متن کاملPregabalin in generalized anxiety disorder: a placebo-controlled trial.
OBJECTIVE Current drug therapies for generalized anxiety disorder have limitations. In a controlled trial, the novel agent pregabalin was studied for the treatment of patients with generalized anxiety disorder. METHOD In this double-blind study, patients with DSM-IV generalized anxiety disorder were randomly assigned to receive pregabalin (150 mg/day or 600 mg/day), lorazepam (6 mg/day), or p...
متن کاملPregabalin for the treatment of generalized anxiety disorder: an update
A PREVIOUS REVIEW SUMMARIZED WHAT WAS THEN KNOWN ABOUT THE POTENTIAL ROLE OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD): this review provides an update on its pharmacological properties and presumed mechanism of action, the liability for abuse, and efficacy and tolerability in patients with GAD. Pregabalin has a similar molecular structure to the inhibitory ...
متن کاملGeneralized Anxiety Disorder in Adults: Focus on Pregabalin
Generalized anxiety disorder (GAD) is a chronic illness which impacts significantly on an individual’s functioning and quality of life. Pregabalin is a novel structural analogue of the inhibitory neurotransmitter GABA, acting to reduce calcium ion flow through the α2δ subunit of pre-synaptic voltage-dependent calcium channels. Pregabalin has been used in treatment of GAD in a total of eight pub...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Noro Psikiyatri Arsivi
سال: 2015
ISSN: 1300-0667,1309-4866
DOI: 10.5152/npa.2015.9964